4.5 Article

Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling

Journal

SCIENCE SIGNALING
Volume 9, Issue 453, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.aaf8566

Keywords

-

Funding

  1. British Heart Foundation [PG/12/1/29276, PG/13/82/30483]
  2. Medical Research Council [MR/J007412/1]
  3. Chief Scientist Office [ETM/226]
  4. Diabetes UK [BDA11/0004309]
  5. National Health Service Greater Glasgow and Clyde Research Endowment Fund [2011REFCH08]
  6. Chest Heart and Stroke Scotland [R10/A131]
  7. Experimental Cancer Medicine Centres
  8. Cancer Research U.K. Centre at Imperial College London, U.K.
  9. Diabetes U.K. [BDA11/0004403, BDA09/0003948]
  10. British Heart Foundation [PG/14/32/30812, PG/13/82/30483, PG/12/1/29276] Funding Source: researchfish
  11. Chief Scientist Office [ETM/226] Funding Source: researchfish
  12. Medical Research Council [MR/J007412/1] Funding Source: researchfish
  13. MRC [MR/J007412/1] Funding Source: UKRI

Ask authors/readers for more resources

Adenosine 5'-monophosphate-activated protein kinase (AMPK) is a pivotal regulator of metabolism at cellular and organismal levels. AMPK also suppresses inflammation. We found that pharmacological activation of AMPK rapidly inhibited the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway in various cells. In vitro kinase assays revealed that AMPK directly phosphorylated two residues (Ser(515) and Ser(518)) within the Src homology 2 domain of JAK1. Activation of AMPK enhanced the interaction between JAK1 and 14-3-3 proteins in cultured vascular endothelial cells and fibroblasts, an effect that required the presence of Ser(515) and Ser(518) and was abolished in cells lacking AMPK catalytic subunits. Mutation of Ser(515) and Ser(518) abolished AMPK-mediated inhibition of JAK-STAT signaling stimulated by either the sIL-6R alpha/IL-6 complex or the expression of a constitutively active V658F-mutant JAK1 in human fibrosarcoma cells. Clinically used AMPK activators metformin and salicylate enhanced the inhibitory phosphorylation of endogenous JAK1 and inhibited STAT3 phosphorylation in primary vascular endothelial cells. Therefore, our findings reveal a mechanism by which JAK1 function and inflammatory signaling may be suppressed in response to metabolic stress and provide a mechanistic rationale for the investigation of AMPK activators in a range of diseases associated with enhanced activation of the JAK-STAT pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available